Routine clinical care data on the association of PD-L1 expression with EGFR and KRAS mutations, and survival in stage III unresected NSCLC patients are limited, but may be important to characterize the therapeutic outlook for patients. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.